Nanocopoeia Drug Patent Portfolio
Nanocopoeia owns 1 orange book drug protected by 3 US patents Given below is the list of Nanocopoeia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11202778 | Amorphous solid dispersions of dasatinib and uses thereof | 22 Jan, 2041 | Active |
| US11298356 | Amorphous solid dispersions of dasatinib and uses thereof | 22 Jan, 2041 | Active |
| US11324745 | Amorphous solid dispersions of dasatinib and uses thereof | 22 Jan, 2041 | Active |
Latest Legal Activities on Nanocopoeia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nanocopoeia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Recordation of Patent Grant Mailed
Critical
| 10 May, 2022 | US11324745 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 May, 2022 | US11324745 |
|
Email Notification
Critical
| 21 Apr, 2022 | US11324745 |
|
Issue Notification Mailed
Critical
| 20 Apr, 2022 | US11324745 |
| Dispatch to FDC | 12 Apr, 2022 | US11324745 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Apr, 2022 | US11298356 |
|
Application Is Considered Ready for Issue
Critical
| 12 Apr, 2022 | US11324745 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Apr, 2022 | US11298356 |
| Printer Rush- No mailing | 06 Apr, 2022 | US11324745 |
|
Pubs Case Remand to TC
Critical
| 01 Apr, 2022 | US11324745 |
|
Email Notification
Critical
| 01 Apr, 2022 | US11324745 |
|
Email Notification
Critical
| 01 Apr, 2022 | US11298356 |
|
PG-Pub Issue Notification
Critical
| 31 Mar, 2022 | US11324745 |
|
PG-Pub Issue Notification
Critical
| 31 Mar, 2022 | US11298356 |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Mar, 2022 | US11298356 |
Nanocopoeia's Family Patents
Nanocopoeia Drug List
Given below is the complete list of Nanocopoeia's drugs and the patents protecting them.
1. Phyrago
Phyrago is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11202778 | Amorphous solid dispersions of dasatinib and uses thereof |
22 Jan, 2041
(16 years from now)
| Active |
| US11298356 | Amorphous solid dispersions of dasatinib and uses thereof |
22 Jan, 2041
(16 years from now)
| Active |
| US11324745 | Amorphous solid dispersions of dasatinib and uses thereof |
22 Jan, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Phyrago's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List